Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Syros Pharmaceuticals

Explore full profile

Redefining the power of small molecules to control gene expression and to provide a profound benefit for patients

Cambridge, United StatesFounded 2012Biotech & Life Sciences
Valuation $11K Market cap · 2026
Revenue $9.9M Latest reported FY

About Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative gene control medicines to treat cancer and genetic diseases. The company operates in the healthcare and biotechnology market, primarily serving patients with acute myeloid leukemia and select solid tumors. Syros' business model revolves around the research, development, and commercialization of small molecule therapies that precisely control gene expression. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary medicines. Syros is advancing a pipeline that includes two investigational medicines in clinical trials and multiple programs in preclinical development. The company's approach leverages its expertise in gene control to create targeted therapies that aim to transform patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2012
Headquarters
Cambridge, United States
Listing
IPO 2016
Sector
Biotech & Life Sciences

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Series B and later14 investors entered at this stage

  • Deerfield
  • Oxford Finance
  • Bain Capital
  • Bain Capital Life Sciences
  • Ally Bridge Group
  • Samsara BioCapital
  • Omega Funds
  • EcoR1 Capital
  • OrbiMed
  • Adage Capital
  • Invus
  • Dafna Capital Management
  • Deep Track Capital
  • Blue Owl Capital

Talent

Book a demo to see the people
Team profiled 26 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Syros Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Syros Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles